Market Newsdesk

NEW YORK, April 23, 2026 (GLOBE NEWSWIRE) — DoubleVerify (NYSE: DV), the leading software platform to verify media quality, optimize ad performance and prove campaign outcomes, today announced that it has achieved Media Rating Council (MRC) accreditation for TikTok Video Viewability, becoming the first measurement vendor to receive the accreditation. This milestone underscores DV’s commitment to delivering the highest standards of measurement accuracy and transparency, and further demonstrates the company’s alignment with the MRC accreditation process as a critical layer of accountability in digital advertising.

“We are proud to be the first measurement provider to achieve MRC accreditation for TikTok video viewability reporting,” said Mark Zagorski, CEO of DoubleVerify. “As advertising investment continues to grow across video-centric social platforms like TikTok, independent verification plays a critical role in ensuring transparency and accountability. With accredited measurement informed by tens of trillions of historical ad transactions, advertisers can evaluate campaign effectiveness with greater confidence and ensure their media investments deliver real value.”

The accreditation covers DV’s direct measurement and reporting of video ads served to the TikTok mobile app, including impressions, viewable impressions and related viewability metrics, as well as sophisticated invalid traffic (SIVT) filtration. Already accredited for open web inventory, these metrics are now extended to TikTok campaigns, with reporting available through a dedicated dashboard within DV Pinnacle^®, the company’s unified service and analytics reporting platform.

“We congratulate DoubleVerify for extending their Video Viewability and SIVT accreditation to include measurement of TikTok traffic as well as continued accreditation of Property Level Ad Verification and Attention”, said George Ivie, MRC CEO. “This accreditation demonstrates DoubleVerify’s continued commitment to independent validation of compliance with industry standards.”

DV also achieved MRC accreditation across two key measurement capabilities, including:

• Extended DV Authentic Attention^® accreditation, now covering metrics for authentic non-viewable and authentic modeled video impressions.
• New property-level ad verification language accreditations, bringing DV’s coverage to 55 accredited languages for domain and mobile app environments and 10 languages for CTV applications.

DV first earned MRC accreditation in February 2013 and has an extensive suite of accredited pre- and post-bid products across display, video and connected TV environments, for which accreditation was continued this year. For a full list of DV’s MRC accreditations, visit here.

About DoubleVerify

DoubleVerify (“DV”) (NYSE: DV) is the industry’s leading media effectiveness platform that leverages AI to drive superior outcomes for global brands. By powering media efficiency and performance, DV strengthens the online advertising ecosystem, preserving the fair value exchange between buyers and sellers of digital media. Learn more at www.doubleverify.com.

Chris Harihar
646-535-9475
[email protected]

DUBAI, United Arab Emirates, April 23, 2026 (GLOBE NEWSWIRE) — Micropolis Holding Company (NYSE American: MCRP) (“Micropolis” or the “Company”), a leading UAE-based developer of autonomous mobile robots and AI-enabled systems, today announced the signing of an engineering and manufacturing agreement with DP World, one of the world’s leading providers of smart logistics and trade solutions.

The agreement marks a significant step in Micropolis’ expansion within the critical infrastructure and industrial industry, enabling the Company to collaborate with one of the world’s most established logistics operators on the advancement of next-generation automation technologies.

Under this agreement, Micropolis will work alongside DP World to support the manufacturing and deployment of a container ascending system designed to enhance operational efficiency, safety, and performance across targeted operational use cases. The collaboration is aligned with DP World’s broader commitment to innovation and the adoption of advanced technologies to optimize global trade operations.

“Being selected by DP World to deliver a program of this technical rigor validates the engineering discipline we have built at Micropolis,” said Fareed Aljawhari, Founder and Chief Executive Officer of Micropolis. “It also marks a significant step further into the maritime and port-automation segment, and reflects the confidence global operators are placing in UAE-built, vertically integrated robotics capabilities. We look forward to supporting DP World’s continued innovation at Jebel Ali and to building a durable, long-term partnership.”

This agreement represents for Micropolis another engineering and manufacturing services mandate with a global port and logistics operator, and extends the Company’s footprint beyond its public-safety and smart-city programs into maritime and industrial-logistics automation, one of the fastest-growing segments of the global automation market.

The collaboration builds on Micropolis’ core capabilities in robotics, AI-driven systems, and integrated automation platforms, further strengthening its position as a key technology partner in high-impact sectors.

While specific project details remain subject to ongoing development and confidentiality frameworks, the agreement establishes a foundation for future initiatives that will leverage Micropolis’ technology to support innovation across logistics and infrastructure ecosystems.

About Micropolis Robotics

Micropolis is a UAE-based company specializing in the design, development, and manufacturing of unmanned ground vehicles (UGVs’), AI systems, and smart infrastructure for urban, security, and industrial applications. The Company’s vertically integrated capabilities cover everything from mechatronics and embedded systems to AI software and high-level autonomy.

For more information, please visit www.micropolis.ai.

Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. You can identify forward-looking statements by the fact that they do not relate strictly to historical or current facts. These statements may include words such as “anticipate”, “estimate”, “expect”, “project”, “plan”, “intend”, “believe”, “may”, “will”, “should”, “can have”, “likely” and other words and terms of similar meaning. Forward-looking statements represent Micropolis’ current expectations regarding future events and are subject to known and unknown risks and uncertainties that could cause actual results to differ materially from those implied by the forward-looking statements. These statements are subject to uncertainties and risks including, but not limited to, the uncertainties related to market conditions and other factors discussed in the “Risk Factors” section of the registration statement filed by the Company with the SEC. For these reasons, among others, investors are cautioned not to place undue reliance upon any forward-looking statements in this press release. Additional factors are discussed in the Company’s filings with the SEC, which are available for review at www.sec.gov. The Company undertakes no obligation to publicly revise these forward-looking statements to reflect events or circumstances that arise after the date hereof.

Micropolis Investor Contact:

KCSA Strategic Communications
Valter Pinto, Managing Director
PH: (212) 896-1254
[email protected]

– PRIDCor Therapeutics Granted Global Development and Commercialization License for IMC-1 and IMC-2 Assets for All Indications, including Fibromyalgia and Long-COVID –

– Dogwood Granted a Tiered Royalty up to 15% on Net Sales –

– Dogwood Entitled to a Percentage of Future Development and Regulatory Milestones, as well as 9% of Future Capital Raised by PRIDCor to Advance Development of IMC-1 and IMC-2 –

ALPHARETTA, Ga., April 23, 2026 (GLOBE NEWSWIRE) — Dogwood Therapeutics, Inc. (NASDAQ: DWTX) (“Dogwood” or the “Company”), a company that focuses on developing new medicines to treat pain and neuropathy, today announced a global development and commercialization partnership with PRIDCor Therapeutics, LLC (“PRIDCor”), a clinical-stage biopharmaceutical company developing antiviral therapies for infection-associated chronic illnesses including Long-COVID, for Dogwood’s anti-viral candidates, IMC-1 and IMC-2. The agreement includes potential payments of up to $100 million to Dogwood and its current and former shareholders.

Dogwood Therapeutics previously announced its intention to explore partnership opportunities to advance its combination antiviral drug candidates and shift its primary focus to advancing its Na_V 1.7 inhibitor, Halneuron^®, to treat both chronic and acute pain conditions. Dogwood subsequentially in-licensed SP16, administered via intravenous formulation, as a complement to its lead asset Halneuron^®, further deepening the Company’s focus on developing new treatments for chemotherapy induced pain and neuropathy.

Consistent with its prior announcement, Dogwood has entered into an agreement with PRIDCor pursuant to which PRIDCor will be fully responsible for financing and executing future development, commercialization and intellectual property maintenance for both IMC-1 and IMC-2. In exchange, Dogwood is entitled to a tiered royalty on net sales of up to 15% upon commercialization of IMC-1 or IMC-2. Further, Dogwood is entitled to 9% of all future capital raised by PRIDCor to advance IMC-1 or IMC-2, as well as future PRIDCor partnership-related development and regulatory payments associated with IMC-1 or IMC-2. Potential payments to Dogwood under the development partnership are capped at $100 million.

“This unique IMC-1 and IMC-2 development and commercialization partnership enables the development of these two novel assets with potential to create significant value to Dogwood and its shareholders in two ways,” commented Greg Duncan, Chairman and Chief Executive Officer of Dogwood. “Future monetary consideration associated with this agreement can reduce future corporate research and operational capital requirements, while at the same time maximizing our internal focus on developing Halneuron^® and SP16 to their full potential.”

To the extent that any payment to Dogwood resulting from the development partnership constitutes either an “Upfront Payment” or a “Milestone Payment” under the terms and conditions applicable to the contingent value rights (“CVRs”) issued by Dogwood on October 17, 2024, Dogwood will cause any required amounts to be delivered to the rights agent for further payment to holders of the CVRs.

About Dogwood Therapeutics:

Dogwood Therapeutics (Nasdaq: DWTX) is a development-stage biopharmaceutical company focused on developing new medicines to treat pain and neuropathic disorders. The Dogwood research pipeline includes two first-in-class development candidates, Halneuron^® and SP16 IV.

Our lead product candidate, Halneuron^®, is in Phase 2b development to treat pain conditions including the neuropathic pain associated with chemotherapy treatment. Halneuron^® has been granted fast track designation from the FDA for the treatment of CINP. Halneuron^® is a non-opioid, Na_V 1.7 analgesic which is a highly specific voltage-gated sodium channel modulator, a mechanism known to be effective for reducing pain transmission. In clinical studies, Halneuron^® treatment has demonstrated pain reduction in pain related to general cancer and in pain related to chronic chemotherapy-induced neuropathic pain (“CINP”). SP16 IV is a low-density lipoprotein receptor related protein-1 agonist (LRP1) with potential to treat neuropathy and prevent or repair nerve damage following chemotherapy. SP16 acts as an LRP1 agonist that in turn provides alpha-1-antitrypsin-like activity. Consistent with alpha-1-antitrypsin anti-inflammatory and immunomodulatory actions, SP16 preclinically demonstrated anti-inflammatory (analgesic) action via potential reductions in IL-6, IL-8, IL1B and TNF-alpha levels, as well as potential to repair damaged tissue via increases in pAKT and pERK that regulate fundamental processes like growth, proliferation and survival. The forthcoming SP16 IV Phase 1b chemotherapy-induced pain and peripheral neuropathy trial is fully funded by the National Cancer Institute.

Dogwood Therapeutic’s largest shareholder is a member of CK Life Sciences Int’l., (Holdings) Inc., which is listed on the Hong Kong Stock Exchange (Stock code: 0775). For more information, please visit www.dwtx.com.

Forward-Looking Statements:

Statements in this press release contain “forward-looking statements,” within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as “anticipate,” “believe,” “contemplate,” “could,” “estimate,” “expect,” “intend,” “seek,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “suggest,” “target,” “aim,” “should,” “will,” “would,” or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on Dogwood’s current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict, including risks related to the completion, timing and results of current and future clinical studies relating to Dogwood’s product candidates, as well as PRIDCor’s ability to successfully develop IMC-1 or IMC-2. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. These and other risks and uncertainties are described more fully in the section titled “Risk Factors” in the most recently filed Annual Report on Form 10-K, which has been filed with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date, and Dogwood undertakes no duty to update such information except as required under applicable law.

Investor Relations:

Dan Ferry
Managing Director
LifeSci Advisors, LLC
[email protected]

SAN DIEGO, April 23, 2026 (GLOBE NEWSWIRE) — Connect Biopharma Holdings Limited (Nasdaq: CNTB) (Connect Biopharma, Connect or the Company), a clinical-stage biopharmaceutical company focused on transforming care for the treatment of inflammatory diseases, today announced that the independent Data Monitoring Committee (DMC) overseeing its Phase 2 Seabreeze STAT asthma and COPD trials evaluating rademikibart, the Company’s next-generation, potentially best-in-class anti-interleukin-4-receptor alpha (IL-4Rα) antibody, has completed its review of the pre-specified interim analysis of efficacy with no recommendation for change in the sample size.

“Based on the DMC’s review of interim efficacy results from our ongoing Seabreeze STAT acute asthma and COPD studies, enrollment will continue as planned with no change in sample size,” said Barry Quart, Pharm.D., CEO and Director of Connect Biopharma. Rademikibart continues to be well tolerated in these studies of patients experiencing acute exacerbations. We continue to believe that rademikibart has the potential to deliver differentiated efficacy and safety in patients with type 2 asthma and COPD experiencing acute exacerbations. We remain on track to report topline results from both Seabreeze STAT studies mid-year.”

The independent DMC reviewed interim data based on a pre-specified analysis of treatment failure at 28 days, the rate of new exacerbations through 28 days, and the change from baseline in FEV₁ following treatment of a minimum of 50 patients in each study with at least 28 days of follow-up.

The DMC also conducts a review of the safety data for both studies on a regular basis and indicated that it has no safety concerns. To date, there have been no treatment-related serious adverse events or severe adverse events, and no discontinuations due to an adverse event in either study.

Connect expects to report topline data from both ongoing Phase 2 Seabreeze STAT studies of rademikibart for acute exacerbations of asthma and of COPD in mid-2026 and plans to move quickly to meet with the U.S. Food and Drug Administration (FDA) to gain alignment on a Phase 3 program.

About Rademikibart

Rademikibart is a fully human monoclonal antibody targeting interleukin-4 receptor alpha (IL-4Rα), a common subunit of interleukin-4 receptor (IL-4) and interleukin-13 receptor (IL-13). We believe that by binding with IL-4Rα, rademikibart can block the functions of IL-4 and IL-13 effectively, thereby blocking the T helper 2 (Th2) inflammatory pathway to achieving the goal of treating Th2 related inflammatory diseases such as atopic dermatitis, asthma and COPD.

About Connect Biopharma

Connect Biopharma is a clinical-stage biopharmaceutical company dedicated to transforming care for asthma and COPD. Headquartered in San Diego, California, the Company is advancing rademikibart, a next-generation, potentially best-in-class antibody designed to target IL-4Rα. The Company is currently conducting global clinical studies of rademikibart for the treatment of acute exacerbations of asthma and COPD, areas with significant unmet need. Connect has granted an exclusive license to Simcere Pharmaceutical Co., Ltd., for rademikibart in Greater China. Under the exclusive license and collaboration agreement, Connect is eligible to receive remaining milestone payments up to an aggregate amount of approximately $110 million upon the achievement of certain development, regulatory and commercial milestones. Connect is also eligible to receive royalties at tiered percentage rates up to low double-digit percentages on net sales in Greater China.

For more information visit www.connectbiopharma.com.

Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended (the Act). Forward-looking statements are statements that are not of historical fact and include, without limitation, statements regarding future events, our future financial condition, results of operations, business strategy and plans, prospective products (as well as their potential to achieve a differentiated, competitive, or favorable benefit or profile or trend, including on safety, tolerability, improvement, maintenance, clinical response, dosing, efficacy and/or convenience), statements regarding any interim analysis or interim, topline or preliminary data and whether the same is indicative of safety, efficacy, final trial results or likelihood of regulatory approval for our product candidates, planned or expected product approval applications or approvals, anticipated milestones and royalties, expected data readouts and enrollments, research and development plans and costs, potential future partnerships, expectations about existing partnerships, timing and likelihood of success, objectives of management for future operations, future results of anticipated product development efforts, adequacy of existing cash and potential partnership funding to fund operations and capital expenditure requirements, anticipated patient populations or market opportunities for our prospective products, if approved, as well as statements regarding industry trends. These statements are based on management’s current expectations of future events only as of the date of this press release and are inherently subject to a number of risks, uncertainties and assumptions, some of which cannot be predicted or quantified and some of which are beyond our control, including, among other things: the ability of our clinical trials to demonstrate safety and efficacy of our product candidates and other positive results; whether we or our current or future partners will need expanded or additional trials in order to obtain regulatory approval for our product candidates; the timing and results of any planned interactions with the FDA; our ability to obtain and maintain regulatory approval of our product candidates; existing regulations and regulatory developments in the U.S., the People’s Republic of China, Europe and other jurisdictions; the ability of our current cash and investments position to support planned operations; our plans and ability to obtain, maintain, protect and enforce our intellectual property rights and our proprietary technologies, including extensions of existing patent terms where available; our continued reliance on third parties to conduct additional clinical trials of our product candidates, and for the manufacture of our product candidates for preclinical studies and clinical trials; and the degree of market acceptance of our product candidates, if approved, by physicians, patients, healthcare payors and others in the medical community.

Words such as “aim,” “anticipate,” “believe,” “could,” “expect,” “feel,” “goal,” “intend,” “may,” “optimistic,” “plan,” “potential,” “promising,” “will,” and similar expressions are intended to identify forward-looking statements, though not all forward-looking statements necessarily contain these identifying words. The inclusion of forward-looking statements should not be regarded as a representation by Connect Biopharma that any of its expectations, projections or plans will be achieved. Actual results may differ materially due to the risks and uncertainties inherent in our business and other risks described in our filings with the U.S. Securities and Exchange Commission (SEC). Further information regarding these and other risks is included under the heading “Risk Factors” in our annual and periodic reports filed with the SEC. These forward-looking statements should not be taken as forecasts or promises nor should they be taken as implying any indication, assurance or guarantee that the assumptions on which such forward-looking statements have been made are correct or exhaustive or, in the case of the assumptions, fully stated in this press release. Drug development and commercialization involve a high degree of risk, and only a small number of research and development programs result in commercialization of a product. Results in early-stage clinical trials may not be indicative of full results or results from later stage or larger scale clinical trials and do not ensure regulatory approval. You are cautioned not to place undue reliance on the scientific data presented or these forward-looking statements, which speak only as of the date of this press release. Except as required by law, Connect Biopharma undertakes no obligation to publicly update any forward-looking statements, whether because of new information, future events or otherwise. Connect Biopharma claims the protection of the safe harbor for forward-looking statements contained in the Act for all forward-looking statements.

This press release discusses our product candidate, rademikibart, which is under clinical investigation and has not yet been approved for marketing by the FDA, the National Medical Products Administration, or by any other regulatory agency. No representation is made as to the safety or effectiveness of rademikibart for the uses for which it is being studied. The trademarks included herein are the property of the owners thereof and are used for reference purposes only.

Investor Relations Contact:

Alex Lobo
Precision AQ
[email protected]
(212) 698-8802

Media Contact:

Ignacio Guerrero-Ros, Ph.D., or David Schull
Russo Partners, LLC
[email protected]
[email protected]
(858) 717-2310 or (646) 942-5604

MIAMI, April 23, 2026 (GLOBE NEWSWIRE) — Defiance ETFs today announced the launch of the Defiance Daily Target 2X Long STX ETF (STXL), expanding its lineup of single-stock leveraged ETFs designed for active traders seeking amplified exposure to individual equities.

The Defiance Daily Target 2X Long STX ETF is designed for traders seeking magnified, short-term bullish exposure to Seagate Technology Holdings plc (NASDAQ: STX) (the “Underlying Security”). By seeking to deliver 200% of the daily percentage change in the share price of STX, the Fund enables investors to express high-conviction, tactical views on the company within the accessibility and transparency of an exchange-traded fund.

Investment Objective

The Fund seeks daily investment results, before fees and expenses, of two times (200%) the daily percentage change in the share price of Seagate Technology Holdings PLC (Nasdaq: STX). The Fund does not seek to achieve its stated investment objective for a period other than a single trading day.

About Seagate Technology Holdings plc

Seagate Technology Holdings plc is a leading provider of data storage solutions, offering hard disk drives, solid-state drives, and data management technologies used across enterprise, cloud, and consumer applications. As global data creation continues to expand, Seagate plays a critical role in enabling scalable storage infrastructure.

An investment in the Fund is not a direct investment in Seagate Technology Holdings plc.

The Fund is not suitable for all investors. The Fund is designed to be utilized only by knowledgeable investors who understand the potential consequences of seeking daily leveraged (2X) investment results, understand the risks associated with the use of leverage, and are willing to monitor their portfolios frequently.

The Fund is not intended to be used by, and is not appropriate for, investors who do not intend to actively monitor and manage their portfolios. The Fund pursues daily leveraged investment objectives, which means it is riskier than alternatives that do not use leverage. The Fund magnifies the performance of Seagate Technology Holdings plc (NASDAQ: STX) (the “Underlying Security”) and is designed strictly for short-term use. For periods longer than a single day, the Fund’s performance will be the result of compounded daily returns, which is very likely to differ from 200% of the return of STX over the same period. It is possible that investors could lose their entire principal within a single trading day.

About Defiance ETFs

Founded in 2018, Defiance is at the forefront of ETF innovation. Defiance is a leading ETF issuer specializing in thematic, income, and leveraged ETFs. Our first-mover leveraged single-stock ETFs empower investors to take amplified positions in high-growth companies, providing precise leverage exposure without the need to open a margin account.

IMPORTANT DISCLOSURES

Defiance ETFs LLC is the ETF sponsor. The Fund’s investment adviser is Tidal Investments, LLC (“Tidal” or the “Adviser”).

The Fund’s investment objectives, risks, charges, and expenses must be considered carefully before investing. The prospectus and summary prospectus contain this and other important information about the investment company. Please read the prospectus and/or summary prospectus carefully before investing. Hard copies can be requested by calling 833.333.9383.

Investing involves risk. Principal loss is possible. As an ETF, the Fund may trade at a premium or discount to NAV. Shares are bought and sold at market price (not NAV) and are not individually redeemed from the Fund. A portfolio concentrated in a single issuer may be subject to a higher degree of risk. There is no guarantee the Fund’s strategy will be properly implemented, and an investor may lose some or all of its investment.

STX Price Decline Risk. As part of the Fund’s leveraged investment strategy, the Fund enters into swap agreements and options contracts based on the share price of Seagate Technology Holdings plc (NASDAQ: STX) (the “Underlying Security”). This strategy subjects the Fund to certain of the same risks as if it owned shares of the Underlying Security, even though it does not. By virtue of the Fund’s indirect 2X exposure to changes in the share price of the Underlying Security, the Fund is subject to the risk that the Underlying Security’s share pricedeclines. If the share price of the Underlying Security decreases, the Fund will likely lose value and, as a result, the Fund may suffer significant losses. The Fund may also be subject to the following risks:

Indirect Investment in STX Risk. Seagate Technology Holdings plc is not affiliated with the Trust, the Fund, the Adviser, or their respective affiliates and is not involved with this offering in any way. Seagate Technology Holdings plc has no obligation to consider the Fund or its shareholders in taking any actions that might affect the value of Fund shares.

STX Trading Risk. The trading price of STX may be subject to volatility and could experience wide fluctuations due to company-specific developments, broader market conditions, or external factors. Market perception, short selling activity, and macroeconomic events may disproportionately impact STX’s share price and, in turn, the Fund’s performance.

STX Performance Risk. STX may fail to meet publicly announced expectations or guidance, which could cause its share price to decline. Predicting business performance is inherently uncertain, and any deviation from expectations could materially impact the value of the Fund.

STX Operations and Business Risk. Seagate operates in a highly competitive and rapidly evolving technology environment. Risks include supply chain disruptions, component shortages, pricing pressures, technological obsolescence, and the ability to innovate and maintain market share. These factors may adversely impact STX’s financial performance and stock price.

Technology Sector Risk. Companies in the technology sector may experience rapid changes in product cycles, intense competition, and evolving consumer demand. These companies may also be affected by supply chain disruptions, intellectual property risks, and changes in interest rates, which may adversely impact STX’s performance.

Single Issuer Risk. Issuer-specific attributes may cause an investment in the Fund to be more volatile than a traditional pooled investment that diversifies risk or tracks the market generally. The Fund’s value may fluctuate more sharply in response to events affecting STX than funds that invest in a broader range of issuers.

Compounding and Market Volatility Risk. The Fund’s performance for periods greater than a trading day will be the result of each day’s returns compounded over the period, which is likely to differ from 200% of the Underlying Security’s performance.

Daily Correlation and Tracking Risk. There is no guarantee that the Fund will achieve a high degree of correlation with 200% of the daily performance of STX. Market disruptions, regulatory restrictions, extreme volatility, or derivative constraints may cause the Fund’s performance to deviate from its objective.

Leverage Risk. The Fund obtains investment exposure in excess of its net assets by utilizing leverage and may lose more money in adverse market conditions than a fund that does not utilize leverage.

Derivatives Risk. The Fund’s use of swap agreements and options contracts involves risks different from, and potentially greater than, those associated with direct investments in securities, including imperfect correlation, increased volatility, and potential losses exceeding the initial investment.

Counterparty Risk. The Fund is subject to counterparty risk due to its use of derivatives. A counterparty’s failure to meet contractual obligations could result in losses or reduced exposure.

Options Contracts Risk. The use of options introduces additional risks, including volatility, time decay, and the possibility that options positions expire worthless, potentially resulting in significant losses.

Swap Agreements Risk. The Fund’s use of swap agreements depends on the availability and willingness of counterparties. If suitable counterparties are unavailable or contracts are terminated, the Fund may not achieve its objective.

Rebalancing Risk. The Fund seeks to rebalance daily to maintain its target exposure. If it is unable to do so effectively, its exposure may deviate from its intended objective, increasing risk.

Intra-Day Investment Risk. Investors purchasing shares intra-day may experience returns that differ from the Fund’s stated objective due to changes in STX’s price throughout the trading day.

Liquidity Risk. Market disruptions or volatility may impair the Fund’s ability to buy or sell instruments at desired prices, potentially impacting performance and increasing trading costs.

High Portfolio Turnover Risk. Daily rebalancing is expected to result in high portfolio turnover, which may increase transaction costs and taxable distributions.

Non-Diversification Risk. The Fund is non-diversified and may invest a larger portion of its assets in a single issuer, increasing sensitivity to STX-specific risks.

New Fund Risk. The Fund is recently organized and has limited operating history, making it more difficult for investors to evaluate performance expectations.

Market and Economic Risk. Broader economic conditions, interest rates, geopolitical events, and market volatility may negatively impact STX and the Fund.

Diversification does not ensure a profit nor protect against loss in a declining market. Brokerage commissions may be charged on trades.

Distributed by Foreside Fund Services, LLC.

Media Contact:
Sylvia Jablonski
[email protected]
833.333.9383

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/e5f902b9-1260-4502-8a19-a53643f76f33

STMicroelectronics to host investor call on the LEO opportunity

Geneva – April 23, 2026 – STMicroelectronics N.V. (NYSE: STM) will host a webcast for investors and analysts on May 4, 2026, on the LEO opportunity, hosted by Remi El-Ouazzane, President of ST’s Microcontrollers, Digital ICs and RF products Group.  

The presentation, starting at 3.30pm CET / 10.30am ET, will be followed by a Q&A session. A live webcast (listen-only mode) of the conference will be accessible at ST’s website, https://investors.st.com, and will be available for replay.

About STMicroelectronics
At ST, we are 48,000 creators and makers of semiconductor technologies mastering the semiconductor supply chain with state-of-the-art manufacturing facilities. An integrated device manufacturer, we work with more than 200,000 customers and thousands of partners to design and build products, solutions, and ecosystems that address their challenges and opportunities, and the need to support a more sustainable world. Our technologies enable smarter mobility, more efficient power and energy management, and the wide-scale deployment of cloud-connected autonomous things. We are on track to be carbon neutral in all direct and indirect emissions (scopes 1 and 2), product transportation, business travel, and employee commuting emissions (our scope 3 focus), and to achieve our 100% renewable electricity sourcing goal by the end of 2027. Further information can be found at www.st.com  

For more information, please contact: 



INVESTOR RELATIONS 
Jérôme Ramel 
EVP Corporate Development & Integrated External Communication 
Tel: +41.22.929.59.20 
[email protected]   

MEDIA RELATIONS 
Alexis Breton 
Group VP Corporate External Communications
Tel: +33.6.59.16.79.08
[email protected]

Attachment

• C3391C – Investor briefing on the LEO opportunity

April 23, 2026  

• Bridge Plus was designed for rare, life-threatening emergencies to help control bleeding during superior vena cava (SVC) tears, which occur in <0.5% of lead extraction procedures [1] but require immediate intervention
• Bridge Plus allows for rapid response when every second counts by deploying in under two minutes [2] and stopping up to 90% blood loss [3], helping stabilize patients with 30 minutes of hemostasis [4]
• Bridge Plus was built upon proven Bridge Occlusion Balloon technology, used in more than 50,000 U.S. procedures [5,*], with evidence showing improved survival when staged in advance [6,**]

Amsterdam, the Netherlands –
Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, announced the launch of the next-generation Bridge Plus Occlusion Balloon, designed to help electrophysiology teams rapidly control bleeding and stabilize patients during rare but life-threatening superior vena cava (SVC) tears in transvenous lead extraction (TLE) procedures. Building on technology used in more than 50,000 procedures [5*], Bridge Plus enables electrophysiology teams to respond in minutes – helping stabilize patients and buy critical time for surgical repair [2-4].

Lead extraction procedures are commonly performed to remove leads from cardiac implantable electronic devices (CIEDs), such as pacemakers or defibrillators, due to damaged, infected or malfunctioning leads. While there is evidence of lead extraction’s safe use [7,8], SVC tears, occurring in fewer than 0.5% of cases [1], can quickly become fatal without immediate intervention.

Bridge Plus is designed to provide temporary vessel occlusion, helping reduce blood loss, maintain hemostasis, and stabilize patients during emergencies. The balloon can deploy in less than two minutes [2], stop up to 90% blood loss [3], and maintain acceptable hemostasis for at least 30 minutes [4]. This provides physicians with critical time to stabilize patients and prepare for surgical repair.

“Ensuring procedural safety is a top priority for electrophysiology teams,” said Stacy Beske, Business Leader, Image-Guided Therapy Devices at Philips. “Bridge Plus builds on established technology to help physicians prepare for rare SVC tears and respond quickly with the control needed to stabilize patients and transition to surgery.”

Clinical evidence highlights the importance of being prepared for this emergency scenario, with studies showing that survival rates in SVC tear events improved from 56.9% to 88.2% when an occlusion balloon was staged and available during procedures [6, 7].

“Although superior vena cava tears are rare, they represent one of the most critical emergencies that can occur during lead extraction,” said Dr. Thomas Callahan, an electrophysiologist at Cleveland Clinic who studied the technology***. “Having an occlusion balloon staged and ready can significantly improve response time when every second matters. This technology may help teams prepare for these rare but serious events and support safer lead extraction procedures.”

Prophylactic balloon set up brings additional benefits during TLE procedures, including individualized balloon staging for each patient, and the ability to deploy Bridge Plus if fluoroscopy is no longer available.

Bridge Plus is a low-pressure, compliant occlusion balloon with radiopaque markers designed for accurate placement and compatibility with a wide range of patient anatomies [9]. The device expands Philips’ portfolio of lead management solutions supporting safe and effective extraction procedures.

The Bridge Plus Occlusion Balloon is now commercially available in the United States, with international availability expected later in 2026, pending country registrations. The solution will also be showcased at Heart Rhythm Society (HRS) 2026, taking place April 24-26 in Chicago, IL.

For more information, visit the Philips Bridge Plus Occlusion Balloon product page.

*Cases performed in United States since Bridge launch in 2016. 
** When staging the Bridge Balloon versus when no Bridge balloon is used.
*** Dr. Callahan discloses consulting payments from Philips North America LLC for training and education services.

[1] Azarrafiy, Ryan et al. “Endovascular Occlusion Balloon for Treatment of Superior Vena Cava Tears During Transvenous Lead Extraction: A Multiyear Analysis and an Update to Best Practice Protocol.” Circulation. Arrhythmia and electrophysiology vol. 12,8 (2019): e007266. doi:10.1161/CIRCEP.119.007266.
[2] Document on file D002023609_A_Bridge M&M Marketing Claims Test Report. Average timed deployment for commercial Bridge was 74.33 seconds (n=6) and Bridge Plus was 58.33 seconds (n=6).
[3] Document on File, D027561 Marketing claims blood loss report for Bridge project 1338 – When deployed, the Bridge Occlusion Balloon reduces blood loss of an SVC tear by 89.7% (α=0.10), on average, in an animal model.
[4] Document on file, D026197 & animal study – NGX028-IS17 – All animals had biological metrics measured for up to 45 minutes during occlusion and 15 minutes post device deployment.
[5] Document on file. LT-002760 Bridge Sales Customers Raw Data.
[6] Bruce L. Wilkoff, MD, FHRS, Roger G. Carrillo, MD, MBA, FHRS, Ryan Azarrafiy, BA, Darren C. Tsang, BS, Thomas A. Boyle, BS. Compliant endovascular balloon reduces the lethality of superior vena cava tears during transvenous lead extractions.
[7] Wazni 0, Epstein LM, Carrillo RG, et al. Lead extraction in the contemporary setting: the LExlCon study: an observational retrospective study of consecutive laser lead extractions. J Am Coll cardiol. 2010;55(6):579-586.
[8] Bongiorni MG, Kennergren C, Butter C, et al. The European Lead Extraction ConTRolled (ELECTRa) study: a European Heart Rhythm Association (EHRA) registry of transvenous lead extraction outcomes. Eur Heart J. 2017;38(40):2995-3005.
[9] Document on file, D026203 Engineering Translation Rationale For Bridge, Project #1338 – PR00. The balloon will cover the length and diameter of the SVC in 90% of the population as determined by analysis of 52 patients.

For further information, please contact:

Joost Maltha
Philips Global External Relations
Tel.: +31 610 558 116
E-mail: [email protected]

About Royal Philips 

Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people’s health and well-being through meaningful innovation. Philips’ patient- and people-centric innovation leverages advanced technology and deep clinical and consumer insights to deliver personal health solutions for consumers and professional health solutions for healthcare providers and their patients in the hospital and the home.

Headquartered in the Netherlands, the company is a leader in diagnostic imaging, ultrasound, image-guided therapy, monitoring and enterprise informatics, as well as in personal health. Philips generated 2025 sales of EUR 18 billion and employs approximately 64,800 employees with sales and services in more than 100 countries. News about Philips can be found at www.philips.com/newscenter.

Attachments

• Clinical illustration of the Philips Bridge Plus balloon in use
• The Philips Bridge Plus Balloon, uninflated prior to use
• The inflated Philips Bridge Plus Balloon

NEW YORK — Wix.com Ltd. (Nasdaq: WIX), today announced that it will report its results for the first quarter ended March 30, 2026 before the market opens on Wednesday, May 13, 2026. Management will host a conference call that morning at 8:30 a.m. ET to answer questions about the Company’s financial results. Prior to the conference call, Wix will issue a press release reporting these results along with a shareholder update and additional materials at https://investors.wix.com/.

What:	Wix First Quarter 2026 Results Conference Call
When:	Wednesday, May 13, 2026
Time:	8:30 a.m. ET
Registration:	https://edge.media-server.com/mmc/p/mez38hxp
Replay &	Replay is available for 12 months
Materials:	https://investors.wix.com/

About Wix.com Ltd.

Wix’s vision is to simplify complex technologies and deliver the best tools for every type of user and business to create online. Powered by advanced AI and enterprise-grade infrastructure, Wix is trusted by millions of users worldwide. Founded in 2006 and strengthened by the acquisition in 2025 of Base44, the no-code application platform, Wix is continuing to build for the future of the internet.

For more about Wix, please visit our Press Room
Investor Relations: [email protected]  
Media Relations: [email protected] 

NEW YORK, April 23, 2026 (GLOBE NEWSWIRE) — RH stock dropped approximately 20% after the company reportedly missed the Q4 adjusted EPS consensus by about 30%, and issued FY 2026 guidance below Wall Street expectations. Shareholders who lost money on their RH investment are encouraged to submit their information here to discuss their legal rights. You may also contact Joseph E. Levi, Esq. via email at [email protected] or by telephone at (212) 363-7500.

During the Q3 2025 earnings call on December 11, 2025, CEO Gary Friedman told investors: “We continue to generate industry-leading growth with revenue increasing 9% in the third quarter and up 18% on a two-year basis.” He added: “We are on track to achieve our outlook range of $250 million to $300 million for the year.” RH subsequently reported Q4 results that fell materially short of the figures management had guided investors toward. Revenue growth, adjusted earnings, and free cash flow all fell below guided metrics. The stock opened down more than $20 per share overnight.

On the same Q3 call, management disclosed that its outlook included “a 170-basis-point impact from tariffs net of mitigations.” The company’s later filings indicated that the actual tariff impact was larger than the figure presented to investors. Per the Wall Street Journal, the Company blamed the shortfall largely on the impact of tariffs, highlighting a $30 million negative impact due to tariff-related costs. Ultimately, the Company reported a 190-basis-point impact in Q4.

If you purchased RH shares and suffered a loss, click here to discuss your legal rights with Levi & Korsinsky. You may also contact Joseph E. Levi, Esq. via email at [email protected] or by telephone at (212) 363-7500.

ABOUT LEVI & KORSINSKY, LLP — Over the past 20 years, Levi & Korsinsky has secured hundreds of millions of dollars for aggrieved shareholders. The firm has extensive expertise in complex securities litigation and a team of over 70 employees. For seven consecutive years, Levi & Korsinsky has ranked in ISS Securities Class Action Services’ Top 50 Report.

Frequently Asked Questions About the RH Investigation

Q: What is the RH investigation about? A: Levi & Korsinsky is investigating whether RH and certain of its senior executives made materially false or misleading statements regarding the company’s financial performance, earnings outlook, and tariff exposure. Shares fell more than 20% after the company disclosed results that fell significantly short of prior guidance, causing substantial losses for shareholders.

Q: Who is eligible to participate? A: Investors who purchased RH stock and suffered financial losses may be eligible. Eligibility is based on purchase timing and documented losses — not on whether you still hold the shares.

Q: What do RH investors need to do right now? A: Gather brokerage records including purchase dates, share quantities, and prices paid. Contact Levi & Korsinsky for a free, no-obligation evaluation at [email protected] or (212) 363-7500.

Q: What if I already sold my RH shares — can I still recover losses? A: Yes. Eligibility is based on when you purchased, not whether you still hold shares. Investors who bought and sold at a loss may still participate.

Q: What does it cost me to participate? A: Nothing. Securities investigations and class actions are handled on a pure contingency basis. No upfront fees, no retainer, no out-of-pocket costs.

CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
33 Whitehall Street, 27th Floor
New York, NY 10004
[email protected]
Tel: (212) 363-7500
Fax: (212) 363-7171

Carthage, MO, April 23, 2026 (GLOBE NEWSWIRE) —  Leggett & Platt (NYSE:LEG), a diversified manufacturer of engineered products serving several major markets, will release first quarter earnings results on Thursday, May 7, 2026 before the market opens.

The Company will not host a call in connection with the earnings release. 

The earnings release will be available on the Investor Relations section of our website.

COMPANY DESCRIPTION: Leggett & Platt (NYSE: LEG) is a diversified manufacturer that designs and produces a broad variety of engineered components and products that can be found in many homes and automobiles. The 143-year-old Company is a leading supplier of bedding components and solutions; automotive seat comfort and convenience systems; home and work furniture components; geo components; flooring underlayment; hydraulic cylinders for material handling and heavy construction applications.

INVESTOR CONTACTS:  
Ryan Kleiboeker, Executive Vice President
(417) 358-8131
[email protected]